Journal article

Combination antiretroviral therapy in 100 HIV-1-infected pregnant women.

Bucceri A, Somigliana E, Matrone R, Ferraris G, Rossi G, Grossi E, Vignali M ...see all

Human reproduction (Oxford, England), vol. 17, issue 2 (2002) pp. 436-41

  • 13


    Mendeley users who have this article in their library.
  • 16


    Citations of this article.
Sign in to save reference


BACKGROUND: In recent years, combination antiretroviral therapy has substantially improved the prognosis of human immunodeficiency virus type-1 (HIV-1) infection. However, at present, information regarding the effects of these regimens during pregnancy is limited.

METHODS: Side-effects, vertical transmission rate and neonatal outcome associated with different combination therapies were evaluated retrospectively in a consecutive series of 100 women who attended the II Department of Obstetrics and Gynecology for the management of HIV-1 infection in pregnancy.

RESULTS: Antiretroviral treatment was initiated at a median of 16 weeks gestation with a range from pre-pregnancy until 31 weeks gestation. Twentythree women continued their pre-pregnancy therapy during the first trimester of gestation. Protease inhibitors were incorporated in 23 of the final therapeutic regimens. Twentyfive women did not receive zidovudine. Most women (97) delivered by Caesarean section and none breast-fed. Prematurity rate for the entire series was 19%. When women who actively used illicit drugs were excluded, only seven of 69 (10%) women were found to deliver prematurely. The use of protease inhibitors was limited by an elevated frequency of severe gastrointestinal disturbances. The rate of congenital malformations did not appear to differ significantly from that reported in the literature for the general population. Only one of 102 live newborns was found to be HIV-1-infected (1.0%, 95% confidence interval; 0.3-4.6%).

CONCLUSIONS: The present findings confirm the remarkable efficacy of combination antiretroviral therapy, Caesarean section and refraining from breast-feeding in lowering the rate of vertical HIV-1 transmission. Moreover, they are suggestive that combination antiretroviral therapy may not be related to major neonatal toxicity. The necessity to discontinue the therapy during the first trimester of pregnancy and to systematically incorporate zidovudine into combination regimens is discussed.

Author-supplied keywords

  • Adult
  • Anti-HIV Agents
  • Anti-HIV Agents: therapeutic use
  • Bottle Feeding
  • Cesarean Section
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • HIV Infections: drug therapy
  • HIV Infections: transmission
  • HIV-1
  • Humans
  • Incidence
  • Infectious Disease Transmission, Vertical
  • Infectious Disease Transmission, Vertical: prevent
  • Obstetric Labor, Premature
  • Obstetric Labor, Premature: epidemiology
  • Pregnancy
  • Pregnancy Complications, Infectious
  • Pregnancy Complications, Infectious: drug therapy
  • Protease Inhibitors
  • Protease Inhibitors: adverse effects
  • Protease Inhibitors: therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • a M Bucceri

  • E Somigliana

  • R Matrone

  • G Ferraris

  • G Rossi

  • E Grossi

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free